Carbapenem-resistant organisms

From IDWiki
Revision as of 12:15, 21 September 2020 by Aidan (talk | contribs)

Background

  • Mechanisms include decreased expression of porins, increased expression of efflux pumps, and carbapenemases

Management

Antibiotic KPC NDM OXA-48 CRPsA CRAcB Stenotrophomonas
aztreonam-avibactam + + + ± +
cefiderocol + + + + + +
ceftazidime-avibactam + + ±
ceftolozane-tazobactam ± ±
eravacycline + + + + +
fosfomycin ± ± ± ±
imipenem-relebactam + ± +
meropenem-vaborbactam +
plazomicin + ± + ±
colistin ± ± ± ± ± ±
tigecycline + + + + +

References

  1. ^  Mical Paul, Elena Carrara, Pilar Retamar, Thomas Tängdén, Roni Bitterman, Robert A. Bonomo, Jan de Waele, George L. Daikos, Murat Akova, Stephan Harbarth, Celine Pulcini, José Garnacho-Montero, Katja Seme, Mario Tumbarello, Paul Christoffer Lindemann, Sumanth Gandra, Yunsong Yu, Matteo Bassetti, Johan W. Mouton, Evelina Tacconelli, Jesús Rodríguez-Baño. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection. 2022;28(4):521-547. doi:10.1016/j.cmi.2021.11.025.